Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
In a recent publication, the results of a large Phase 3 trial comparing solithromycin with moxifloxacin in the treatment of CAP are presented [1]. As this was a global registration trial, we should refer to the indication as CABP, the current FDA acronym for a very defined entity which has some Continue reading Solithromycin CAP Study: Cap the Details (in the Publication)
There are only 3 CDI drugs in wider clinical use: vancomycin, metronidazole, and fidaxomicin. They are from totally different classes and have almost nothing in common except for proven efficacy in C. difficile infection (CDI). Like vancomycin, the entire group of glycopeptide drugs seems to have good activity against C. Continue reading Quo Vadis, CDI Drugs?
Coming back from ECCMID, one gets the impression that we are moving towards an era in which we can diagnose everything but treat nothing. A late breaker session on colistin resistance provided much detail data on the situation in the EU. As we know, colistin resistance conferred by the mcr-1 gene has Continue reading The Brave New World of Infectious Diseases